Nitric oxide depletion is responsible for the adverse effects of vascular endothelial growth factor inhibitors
Jecko Thachil
Correspondence University of Liverpool, Haematology Department, Prescot Street, Liverpool L7 8XP, UK
Email jeckothachil@yahoo.co.uk
Inhibitors of vascular endothelial growth factor, such as bevacizumab, are a promising approach to the treatment of tumors and other angiogenesis-dependent conditions. However, it is becoming increasingly obvious that these drugs can have serious adverse effects including proteinuria, hypertension and thrombotic microangiopathy. This Viewpoint evaluates current evidence to argue that these adverse effects are probably elicited by inhibition of nitric oxide production in the renal vasculature.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
